Authors


Laila M. Castellino, MD, FIDSA

Latest:

Rifaquizinone: A Novel Rifamycin-Quinolone Hybrid Antibiotic

Rifaquizinone is a dual-pharmacophore antibiotic combining rifamycin and a fluoroquinolone-like compound, showing strong bactericidal activity against resistant Staphylococcus aureus strains and biofilms, with promising results for treating prosthetic joint infections (PJI) but limited oral bioavailability.


Jane M. Carlton, PhD

Latest:

Decoding Malaria Parasites to Aid in Potential Treatments and Vaccines

The Johns Hopkins Malaria Research Institute’s work in this area is looking to find ways to identify, for the first time, every single gene in the genome of malaria parasites, which could lead to the development of new treatments or vaccines.



T. Sam Albanesi, MD, MA

Latest:

An Update on Lenacapavir

This new antiretroviral with a unique mechanism of action may be lifesaving for those with treatment-resistant HIV infection.


Jessica Malaty Rivera, MS

Latest:

mRNA COVID-19 Vaccines and Turbo Cancer: The Latest Myth That Won’t Disappear

The continuation of misinformation and disinformation being disseminated in the public is causing more public health communication issues as mistruths associate the vaccines with cancer.


Nisha Patel, PharmD, BCPS

Latest:

To Prophylax or not to Prophylax: Preventing CDI

Clinicians look at optimal approaches for trying to avoid Clostridioides difficile infection (CDI).


Eran Eden, PhD

Latest:

From Pathogen to Infectious Disease Diagnosis: Test Determines Between Bacterial and Viral Infections in 15 Minutes

MeMed CEO Eran Eden, PhD, discusses the MeMed BV test and how it can help make the distinction between the types of infections, aid in patient management, and reduce antimicrobial resistance.


Jenna Salay, BS

Latest:

What's New In 2024: From the CLSI Subcommittee on Antimicrobial Susceptibility Testing

The Clinical and Laboratory Standards Institute (CLSI) Subcommittee on Antimicrobial Susceptibility Testing had its series of meetings to update breakpoints for a variety of classes of antimicrobials.


Alison L. Blackman, PharmD, BCIDP

Latest:

So You Made the Decision to Implement Vancomycin AUC Dosing. Now What?

Since the vancomycin guideline update, institutional leaders have been faced with the challenge of implementing and monitoring AUC-guided dosing.


Sharmeen Roy, PharmD, BCPS

Latest:

AI as a Tool to Support Clinicians, Not Replace Them

Sharmeen Roy, PharmD, BCPS, on artificial intelligence (AI) in improving decision-making, reducing adverse drug events on National Adverse Drug Event Awareness Day, and upcoming research on pediatric dosing at the the Congress of the European Society of Clinical Microbiology and Infectious Diseases.


Ashley L. O’Leary, PHARMD, AAHIVP

Latest:

Outpatient Antimicrobial Stewardship: The Keys to Developing a Successful Program

This form of stewardship can reduce unnecessary antibiotic prescribing, reduce costs, and optimize patient outcomes.


Brandon Dionne, PharmD, BCPS-AQ ID, BCIDP, AAHIVP

Latest:

Going Viral on Social Media: Integrating Digital Tools into Pharmacy Rotations

In the latest Bench to Bedside column, 2 clinicians discuss the benefits of utilizing social media for learning.


Jesse S. Veisblatt, MD

Latest:

Bad Bugs, New Drugs: A Discussion of Selected New Therapeutics From IDWeek 2022

Cefepimetaniborbactam may represent a safe and effective carbapenemsparing agent in cUTI and AP, whereas ridinilazole may play an important role in treating CDI.


Joseph Zackular, PhD

Latest:

While Hospital-Acquired C difficile Cases Have Decreased, Community-Acquired Cases Have Risen

Joseph Zackular, PhD highlights targeting high-risk groups for vaccination and shares insights into the future of mRNA vaccine development for C diff.


Dana Holger, PharmD, MPH, AAHIVP

Latest:

Tricky Infusion Issues and Potential Solutions: OPAT Edition

Outpatient parenteral antimicrobial therapy (OPAT) offers benefits for patients as well as providing cost effectiveness; however, it is not without its challenges. Two clinicians provide insights on this modality.



Emily Jenkins PhD, DVM, BScHon

Latest:

Will the Melting Permafrost Uncover Vector Borne and Zoonotic Pathogens and Release Ancient Infectious Diseases?

With melting ice and the release of ancient viruses, there are concerns around the emergence of potentially unknown infectious diseases. Emily Jenkins PhD, DVM, BScHon, offers insights on “zombie viruses” and says polar bears might hold the key to understanding what lies ahead, and how a One Health approach may help in surveillance and prevention.



Brandon Garcia, PharmD, PGY2

Latest:

New Recommendations for Antibiotic Prophylaxis Prior to Dental Procedures

The American Dental Association (ADA) has updated patient profiles on who should be indicated for antibiotic prophylaxis.


Elizabeth Hastie, MD

Latest:

Long-Acting Injectable HIV Therapy: Addressing Adherence Challenges

Elizabeth Hastie, MD discussed the LATITUDE trial results, highlighting the need for wider access to this treatment, especially for those not virally suppressed, and could help shape future healthcare guidelines.


Sarah Green, PharmD, BCPS, BCIDP, AAHIVP

Latest:

Precision Dosing of To-Marrow: Linezolid Therapeutic Drug Monitoring

Emerging literature suggests therapeutic drug monitoring for this antimicrobial to minimize the risk for linezolid-associated toxicities while maintaining efficacy in select populations.


Bala Subramanian, PhD

Latest:

Bugworks' Antibiotic BWC0977 Targets Resistant Pathogens

Bala Subramanian, PhD, highlights how the novel antibiotic BWC0977, with its dual intravenous and oral formulation, is poised to transform the fight against antimicrobial resistance.


Theodore S. Rader IV, MD, MS

Latest:

Will We Ever See Oral Carbapenems for ESBL Urinary Tract Infections?

Recent issues surrounding the ADAPT-PO and SURE-2 trials place the spotlight on the difficulties developing oral carbapenem-based antibiotics and case their future into doubt.


Christina Yen, MD; Ahmed Abdul Azim, MD; and Preeti Mehrotra, MD, MPH

Latest:

From Single-Use to Multi-Use: A Brief Review of N95 Respirator Decontamination Strategies

This indispensable personal protective equipment did come up in short supply and reuse strategies has become a topic of great interest and research.


Nina Cosdon

Latest:

Unveiling Gender Disparities in Lyme Disease: A Critical Analysis of Persistent Illness

Very few Lyme disease studies consider sex- and gender-based differences. Is this flawing the research?


Kaitlyn Jarrell, PharmD, BCPS, AAHIVP

Latest:

PrEP State of the Union: Adherence, Access, Uptake Issues

Although this form of prophylaxis is highly protective, there are situations in which breakthrough infections occur.


Alyssa Walker, PharmD, BCPS, BCIDP

Latest:

Antibiotic De-Escalation: Is This the Right Outcome Measure?

The proposed clinical benefits of de-escalation has contributed to its lukewarm adoption in some settings. This article looks at the challenges in measuring the impact of de-escalation, and the ongoing search for more meaningful metrics to evaluate the success of antimicrobial stewardship (AMS) programs.


Steven P. LaRosa, MD

Latest:

Ceftriaxone as Definitive OPAT for MSSA Bloodstream Infections

A cautious approach for now is warranted as well as a need for a randomized clinical trial.


Geena Kludjian, PharmD, BCIDP

Latest:

Employee Health After the COVID-19 Pandemic: Stronger Than Yesterday

For providers on the front lines, lessons learned can help inform strategies to enhance the protection of their health going forward.


Paul Offit, MD

Latest:

Measles: The Canary in the Coal Mine for Childhood Vaccine Decline

On the heels of the first death in an ongoing US-based measles outbreak, Paul Offit, MD, discusses how outbreaks are the first sign that childhood vaccination rates are starting to decline.

© 2025 MJH Life Sciences

All rights reserved.